Metropolis Healthcare Q2 FY27 Revenue Up 16% to ₹497 Cr
Metropolis Healthcare announced strong unaudited consolidated financial results for Q2 FY27, with revenue increasing by 16% year-on-year to ₹497 crore and Profit After Tax (PAT) rising by 43% to ₹75 crore. Patient volume grew 10% YoY to 4.1 million, and test volume increased 11% YoY to 8.7 million. B2C revenue grew 17% YoY to ₹289 crore, while B2B revenue rose 15% YoY to ₹208 crore. TruHealth revenue grew 20% YoY to ₹86 crore, and specialty revenue rose 20% YoY to ₹198 crore. Revenue per Patient (RPP) increased 6% YoY to ₹1,221, and Revenue per Test (RPT) improved 5% YoY to ₹572. Tier III cities showed strong growth, with revenue rising around 20% YoY. The company also declared an interim dividend of ₹1 per share.
Key Highlights
- Q2 FY27 revenue surged 16% YoY to ₹497 crore.
- PAT grew significantly by 43% YoY to ₹75 crore.
- Patient and test volumes increased by 10% and 11% respectively.
- Strong growth observed in B2C, B2B, TruHealth, and specialty segments.
- Interim dividend of ₹1 per share declared.
Price Impact
More from METROPOLIS